Innoviva (NASDAQ:INVA) Reaches New 12-Month Low – Here’s Why

Innoviva, Inc. (NASDAQ:INVA – Get Free Report) hit a new 52-week low during mid-day trading on Monday. The stock traded as low as $18.60 and last traded at $18.56, with a volume of 232,807 shares. The stock had previously closed at $19.03.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on INVA. Cantor Fitzgerald reduced their price objective on Innoviva from $36.00 to $34.00 and set an “overweight” rating for the company in a research report on Friday, August 7th. Weiss Ratings upgraded Innoviva from a “hold (c+)” rating to a “buy (b)” rating in a research note on Monday, November 9th. Zacks Research raised Innoviva from a “strong sell” rating to a “hold” rating in a research report on Monday, August 31st. Oppenheimer dropped their target price on Innoviva from $35.00 to $34.00 and set an “outperform” rating on the stock in a research report on Thursday, November 5th. Finally, Wall Street Zen cut Innoviva from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Innoviva has a consensus rating of “Moderate Buy” and a consensus target price of $39.00.

Get Our Latest Research Report on Innoviva

Innoviva Price Performance

The company has a debt-to-equity ratio of 0.23, a quick ratio of 14.58 and a current ratio of 15.44. The business’s 50 day simple moving average is $20.70 and its 200-day simple moving average is $21.85. The stock has a market capitalization of $1.31 billion, a price-to-earnings ratio of 9.26, a price-to-earnings-growth ratio of 4.16 and a beta of 0.38.

Innoviva (NASDAQ:INVA – Get Free Report) last posted its earnings results on Wednesday, November 4th. The biotechnology company reported ($1.03) EPS for the quarter, missing the consensus estimate of $0.52 by ($1.55). Innoviva had a return on equity of 22.91% and a net margin of 44.13%. The firm had revenue of $106.12 million during the quarter, compared to the consensus estimate of $115.31 million. Research analysts anticipate that Innoviva, Inc. will post 1.52 earnings per share for the current year.

Hedge Funds Weigh In On Innoviva

Several hedge funds and other institutional investors have recently made changes to their positions in INVA. Fortitude Family Office LLC bought a new stake in Innoviva during the 3rd quarter valued at $25,000. Parallel Advisors LLC boosted its position in Innoviva by 82.8% during the 1st quarter. Parallel Advisors LLC now owns 1,179 shares of the biotechnology company’s stock worth $27,000 after acquiring an additional 534 shares during the period. Public Employees Retirement System of Ohio acquired a new position in Innoviva during the 2nd quarter worth $30,000. Versant Capital Management Inc grew its stake in shares of Innoviva by 96.5% in the third quarter. Versant Capital Management Inc now owns 1,916 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 941 shares in the last quarter. Finally, Allworth Financial LP bought a new position in shares of Innoviva in the second quarter worth $42,000. 99.12% of the stock is currently owned by institutional investors and hedge funds.

About Innoviva

(Get Free Report)

Innoviva, Inc. is a biopharmaceutical company with two main areas of activity: royalty interests in respiratory medicines developed with GSK and the development and commercialization of specialty medicines. Its respiratory-related royalties include products such as Trelegy Ellipta, Anoro Ellipta and Breo Ellipta, which are used to treat chronic obstructive pulmonary disease and asthma and are marketed by GSK. Through its specialty therapeutics operations, Innoviva focuses on medicines for serious infections and other acute-care conditions.

Recommended Stories

Receive News & Ratings for Innoviva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva and related companies with MarketBeat.com's FREE daily email newsletter.